Jan 8 (Reuters) - Abbvie Inc:
* ABBVIEâ€˜S UPADACITINIB GRANTED BREAKTHROUGH THERAPY DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ATOPIC DERMATITIS Source text for Eikon: Further company coverage:
 